Printer Friendly

Drug combo: double whammy with a bonus.

Drug combo: Double whammy with a bonus

AIDS patients with Kaposi's sarcoma -- a normally rare cancer that strikes many people with AIDS--can benefit from a double-whammy treatment consisting of zidovudine and alpha interferon, a naturlly occurring protein. The double-drug regimen inhibits the spread of HIV and shrinks tumors in some patients at doses low enough to avoid the debilitating side effect stemming from standard does of either drug alone, according to a report in the Aug. 15 ANNALS OF INTERNAL MEDICINE.

H. Clifford Lane at the National Institute of Allergy and Infectious DIseases in Bethesda, Md., and his colleagues studied 22 homosexual or bisexual men with both AIDS and Kaposi's sarcoma. After 12 weeks on the dual regimen, 10 of these patients showed a 50 percent reduction in half their tumors and one showed no evidence of tumors, Lane reports.

In addition, the one-two punch of zidovudine and interferon appeared to stop the spread of HIV. When the researchers tried to culture HIV from the 22 patients' blood samples after 12 weeks of treatment, they found that eight study participants had negative cultures. At the outset of the study, all eight had positive HIV cultures, Lane says.

The findings are significant because many AIDS patients on high doses of zidovudine -- and many AIDS or cancer patients on high doses of infection -- develop severe side effects. The drug combination allows doctors to lower the dose of zidovudine while at the same time retarding HIV's spread and attacking the cancerous tumors, the scientists say.
COPYRIGHT 1989 Science Service, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1989, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:zidovudine and alpha interferon for AIDS-Kaposi's sarcoma patients
Publication:Science News
Date:Aug 26, 1989
Previous Article:Blue-green algae kill HIV in culture.
Next Article:Peatlands: a global warming threat?

Related Articles
Two AIDS drugs may be better than one.
AZT-resistant HIV seen.
Gout drug might cut AZT dosage by half.
AZT causes cancer in lab animals.
Mystery microbe may cause 'AIDS cancer.' (Kaposi's sarcoma)
Critical Kaposi's growth factor identified.
Drug duo uses synergy to fight AIDS virus.
Mathematical model stirs AIDS controversy.
No survival bonus from early AZT.
Mixed results on AZT's survival payoff.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters